Beam Therapeutics Inc.
24.05USD
-0.5100 (-2.08%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BEAM.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 32 | 114 | 10 | 8 | 7 | 30 | 14 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -127 | -107 | -17 | -127 | -120 | -119 | -100 | -107 |
| Net Income | -123 | -94 | 244 | -113 | -102 | -108 | -90 | -97 |
| EPS (Diluted) | -$1.18 | -$0.91 | $2.51 | -$1.10 | -$1.00 | -$1.23 | -$1.09 | -$1.17 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)